AnemiaNCT00211055
A Study to Observe the Causes and Treatment of Anemia in Critically Ill Children
An observational study of Anemia, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
Trial summary
The purpose of this study is to determine the incidence of anemia and blood transfusions and management of these in critically ill children Read more about this study
- Who is it for?
- Ages Up to 17 years
- Conditions the study is for
- Anemia
- How many people
- 1,201 participants
- Where
- No sites listed yet
- Study dates
- Sep 2004to Mar 2005
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 17 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Male or female patients aged 0 to 17 years
- During part 1 of this study, patients must be newly admitted to the Pediatric Intensive Care Unit (PICU) (regardless of stay)
- During part 2 of the study, patients must be newly admitted to the PICU and have stayed there for > = 48 hours
- Patients' legally acceptable representatives must have signed an informed consent
- Patients aged 7 years and above must give assent if or when they are physically capable
Who cannot join
- Premature infants (patients who were born at < = 37 weeks who are < 28 days old)
- Patients who have previously participated in this study
- Patients from a family unwilling to receive blood transfusions (for example for religious reasons)
- Patients who are participating in any other transfusion or blood-related research at the time of entry into the study or any time during the study
- Patients who are known to be pregnant (no pregnancy test will be performed in this study)
- Patients with known or suspected brain death
- Patients who have had a Pediatric Intensive Care Unit (PICU) stay of longer than 72 hours within the 7 days prior to entering the study
About this study
Official title: A Multicenter, Epidemiological, Observational Study of the Management of Anemia in Critically Ill Pediatric Patients
The purpose of this study is to determine the incidence of anemia and blood transfusions and management of these in critically ill children
Read the detailed description
Critically ill patients admitted to the intensive care unit often have anemia from one or more of a number of possible causes including blood loss due to surgery or injury, frequent blood sampling, chronic diseases such as kidney failure or cancer or treatments being received, such as chemotherapy. Although the common treatment for anemia is red blood cell transfusion, the current guidelines for blood transfusions for children are based on available information regarding transfusions in adults. Since many characteristics specific to critically ill children may affect the way in which they respond to anemia and transfusion, additional information is needed to better define guidelines for the prevention and treatment of anemia in critically ill children. This is a multi-center study to collect information regarding the management of anemia in critically ill children. Information needed to evaluate anemia, blood loss and transfusions will be collected from the patients' hospital records. No blood draws or procedures will be required by this survey and no medication will be supplied by the study Sponsor. Each patient's treating physician will be responsible for all decisions regarding his/her clinical care and treatment during the study. Approximately 1200 patients will be enrolled into this study, which is divided into 2 parts. During part 1, at least 400 patients who are newly admitted to the Pediatric Intensive Care Unit (PICU) will be enrolled, regardless of their length of stay in the PICU. During part 2, up to an additional 800 patients who are newly admitted into the PICU and have remained there for > = 48 hours at the time of entry into the study will be enrolled. Information for each patient will be collected for up to 28 days or until time of discharge from the hospital or death of the patient, whichever occurs first. Blood loss will be reported for each day the patient remains in the PICU; information regarding the treatment of anemia, including number and reasons for transfusions will be collected for a maximum of 28 days, regardless of the length of stay in the PICU. Information collected at the time of discharge from the hospital will include date of discharge and whether or not the patient is receiving mechanical assistance to breathe. Several possible hypotheses are being generated in this study: 1) Blood loss due to procedures and routine laboratory tests may be a major cause of anemia and transfusions in critically ill children; 2) Determining significant causes of anemia and blood transfusions in children will allow for better future treatment of anemia; and 3) Pediatric patients who receive blood transfusions have more days on a ventilator (a machine that helps patients who cannot breathe on their own), longer stays in the PICU and decreased organ function. Since the study involves only collection of information, no treatment will be required by the Sponsor and no medication will be supplied by the Sponsor.
- Conditions
- Anemia
- Keywords
- Critically Ill, Intensive Care Unit, Blood transfusion, Blood loss, Pediatric, Children, Anemia, Pediatric Intensive Care Unit, Hemoglobin, Transfusion
- Medical subject headings
- Anemia, Critical Illness, Hemorrhage
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Sep 2005 (estimated)
- Study startSep 2004
- Study completionMar 2005
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AnemiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Time perspective
- Prospective
- Enrolment
- 1,201 participants (actual)
Sponsor and investigators
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Sponsor type
- Industry (pharma, biotech, devices)
- Investigators
- Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial, Study director, Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00211055
- Sponsor's protocol ID
- CR004396
- Status last verified
- Apr 2013
- First submitted
- 13 Sep 2005
- Last updated
- 16 Apr 2013
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Apr 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multicenter, Epidemiological, Observational Study of the Management of Anemia in Critically Ill Pediatric Patients
- ClinicalTrials.gov ID
- NCT00211055
- Acronym / sponsor ID
- CR004396
- Conditions
- Anemia
- Keywords
- Critically Ill, Intensive Care Unit, Blood transfusion, Blood loss, Pediatric, Children, Anemia, Pediatric Intensive Care Unit, Hemoglobin
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,201 participants (actual)
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Industry (pharma, biotech, devices)
- Study start
- Sep 2004
- Study completion
- Mar 2005 (actual)
- First posted
- 21 Sep 2005 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine the incidence of anemia and blood transfusions and management of these in critically ill children
Detailed description
Critically ill patients admitted to the intensive care unit often have anemia from one or more of a number of possible causes including blood loss due to surgery or injury, frequent blood sampling, chronic diseases such as kidney failure or cancer or treatments being received, such as chemotherapy. Although the common treatment for anemia is red blood cell transfusion, the current guidelines for blood transfusions for children are based on available information regarding transfusions in adults. Since many characteristics specific to critically ill children may affect the way in which they respond to anemia and transfusion, additional information is needed to better define guidelines for the prevention and treatment of anemia in critically ill children. This is a multi-center study to collect information regarding the management of anemia in critically ill children. Information needed to evaluate anemia, blood loss and transfusions will be collected from the patients' hospital records. No blood draws or procedures will be required by this survey and no medication will be supplied by the study Sponsor. Each patient's treating physician will be responsible for all decisions regarding his/her clinical care and treatment during the study. Approximately 1200 patients will be enrolled into this study, which is divided into 2 parts. During part 1, at least 400 patients who are newly admitted to the Pediatric Intensive Care Unit (PICU) will be enrolled, regardless of their length of stay in the PICU. During part 2, up to an additional 800 patients who are newly admitted into the PICU and have remained there for > = 48 hours at the time of entry into the study will be enrolled. Information for each patient will be collected for up to 28 days or until time of discharge from the hospital or death of the patient, whichever occurs first. Blood loss will be reported for each day the patient remains in the PICU; information regarding the treatment of anemia, including number and reasons for transfusions will be collected for a maximum of 28 days, regardless of the length of stay in the PICU. Information collected at the time of discharge from the hospital will include date of discharge and whether or not the patient is receiving mechanical assistance to breathe. Several possible hypotheses are being generated in this study: 1) Blood loss due to procedures and routine laboratory tests may be a major cause of anemia and transfusions in critically ill children; 2) Determining significant causes of anemia and blood transfusions in children will allow for better future treatment of anemia; and 3) Pediatric patients who receive blood transfusions have more days on a ventilator (a machine that helps patients who cannot breathe on their own), longer stays in the PICU and decreased organ function. Since the study involves only collection of information, no treatment will be required by the Sponsor and no medication will be supplied by the Sponsor.
Study design
- Time perspective
- Prospective
Who may qualify
- Ages
- Up to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (5 listed)
- Male or female patients aged 0 to 17 years
- During part 1 of this study, patients must be newly admitted to the Pediatric Intensive Care Unit (PICU) (regardless of stay)
- During part 2 of the study, patients must be newly admitted to the PICU and have stayed there for > = 48 hours
- Patients' legally acceptable representatives must have signed an informed consent
- Patients aged 7 years and above must give assent if or when they are physically capable
Key exclusion criteria (7 listed)
- Premature infants (patients who were born at < = 37 weeks who are < 28 days old)
- Patients who have previously participated in this study
- Patients from a family unwilling to receive blood transfusions (for example for religious reasons)
- Patients who are participating in any other transfusion or blood-related research at the time of entry into the study or any time during the study
- Patients who are known to be pregnant (no pregnancy test will be performed in this study)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Apr 2013.
Related trials for Anemia
RecruitingPhase 1/2
The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia
Aplastic Anemia, Refractory
Active, not recruitingPhase 1
A Study of YTS109 Cell Injection in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia
Autoimmune Hemolytic Anemia, Anti-CD19 STAR T-cell Therapy
Not yet recruitingObservational study
Systematic Intraoperative Cell Salvage in On-Pump Cardiac Surgery Within a Mature Patient Blood Management Programme
Cardiac Surgical Procedures, Blood Transfusion
RecruitingPhase 1/2
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
Myelodysplastic Syndromes
RecruitingObservational study
Defining the Natural History of Squamous Cell Carcinoma in Fanconi Anemia
Fanconi Anemia, Inherited Bone Marrow Failure Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial study director
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Questions about this trial
What is this clinical trial studying?
An observational study of Anemia, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Apr 2013. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Apr 2013.